ArticleClinical rheumatology2026
Interstitial lung disease in systemic sclerosis-a retrospective cross-sectional study in Taiwan.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of hematological inflammatory indices with disease activity and interstitial lung disease in systemic sclerosis.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
INTRODUCTION/
objectivesInterstitial lung disease (ILD) is a crucial manifestation of systemic sclerosis (SSc), which has not been studied much in Asians.
methodsThe electronic medical records of 110 SSc patients between April 2000 and December 2020 were comprehensively examined, including clinical manifestations, laboratory tests, pulmonary functions, and high-resolution computerized tomography (HRCT) of the chest.
resultsAmong 26 men and 84 women with a median age of 61 years in SSc cohort, 52 (47.3%) presented with ILD. The actual prevalence of ILD in SSc cohort was estimated between 10.5% and 47.3%. The most common form was usual interstitial pneumonitis (UIP). The total lung capacity (TLC)/diffusion capacity of carbon monoxide (DLCO), renal function, and CRP were poorer in the SSc-ILD who smoked less than the counterpart without ILD. A weighted score incorporated from essential parameters (risk of ILD = TLC - 0.1 × ESR - 1.5 × CRP) has modest power (ROC AUC 0.7242) to predict ILD. The main causes of death in the SSc-ILD were infections (72.7%), pulmonary hypertension (PH, OR = 18.81, 95% CI = 2.11-167.70), and renal failure (OR = 33.6, 95% CI = 2.00-546.10).
conclusionThe SSc-ILD have lower TLC/DLCO, higher CRP, and poorer renal function than the SSc without ILD. Early-onset dyspnea, PH, and renal failure may be independent risk factors for mortality in SSc-ILD. Key Points • 110 SSc (M: F=26:84) were retrospectively analyzed for ILD, with 10.5-47.3% presenting with ILD (UIP the most). • Risk of ILD in SSc = TLC - 0.1 × ESR - 1.5 × CRP can apply in this cohort. • Death originated from infections, PH, and renal failure in addition to early-onset dyspnea in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.